MedTrace Logo

Combining Doxycycline With Bone-Targeted Therapy in Patients With Metastatic Breast Cancer

NCT01847976 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2019-09-06

No results posted yet for this study

Summary

The purpose of this study is to see if women with bone metastases from breast cancer will benefit from the addition of doxycycline to their standard bone-targeted therapy. Participants will be asked to take 100 mg of Doxycycline orally twice a day for 12 weeks. Blood and tissue collection will further define the mechanism of the benefits if there are any.

Conditions

Interventions

DRUG

Doxycycline

Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.

Sponsors & Collaborators

  • Canadian Breast Cancer Foundation

    collaborator OTHER

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Mark Clemons, FRCP · The Ottawa Hospital Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01847976 on ClinicalTrials.gov